BOSTON & NEW YORK--(BUSINESS WIRE)--Stemgent, Inc. and Pfizer Inc. (NYSE: PFE) today announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent. Stemgent provides research tools and services to institutions, companies and universities in advancing in vitro and in vivo non-human stem cell research.